Grifols has acquired its existing portfolio company Alkahest, five years after buying a 45% stake in the Stanford University spinout.

Alkahest, a US-based neurodegenerative disease drug developer spun out of Stanford University, agreed to an acquisition by pharmaceutical firm Grifols for $146m yesterday.
The transaction is subject to regulatory approval and is expected to close early next year.
Founded in 2014, Alkahest is working on therapies based on the company’s map of the human plasma proteome – the set of proteins in the blood plasma – to slow detrimental biological processes of aging.
The spinout has four…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in